Phio Pharmaceuticals Corp. Submits 8-K SEC Filing (0001533040)
Phio Pharmaceuticals Corp. (0001533040) recently submitted an 8-K filing to the Securities and Exchange Commission (SEC), signaling important developments within the company. The significance of this filing lies in the fact that it provides investors and the public with updated information about Phio Pharmaceuticals Corp.’s current operations, financial status, or other material events that may impact the company’s performance.
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing novel therapeutics for the treatment of various diseases. They utilize their proprietary self-delivering RNAi (sd-rxRNA) platform to develop innovative therapies aimed at addressing unmet medical needs. For more information about Phio Pharmaceuticals Corp., you can visit their website here.
The 8-K filing submitted by Phio Pharmaceuticals Corp. falls under the category of SEC forms that are used to inform investors about significant events that are important for transparency and disclosure purposes. These filings are crucial for investors to make informed decisions about their investments and stay updated on the latest developments within the company.
Read More:
Phio Pharmaceuticals Corp. Submits 8-K SEC Filing (0001533040)
